## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.00)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Korea Investment CORP Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251202T112154 | Neutral | Relevance: 99%
- Korea Investment CORP significantly increased its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 12.5% in Q2 2025, bringing its total holdings to 111,789 shares valued at approximately $10.20 million. This increase occurred amidst mixed analyst ratings, with an average "Hold" rating and an average price target of $109, despite recent downgrades from some firms and a "Strong Buy" from another. Zimmer Biomet also reported a slight beat on quarterly EPS and provided FY2025 guidance.

**2. Zimmer Biomet Holdings, Inc. $ZBH Stock Position Decreased by JPMorgan Chase & Co.**
- Source: MarketBeat | 20251130T104147 | Neutral | Relevance: 99%
- JPMorgan Chase & Co. significantly decreased its stake in Zimmer Biomet Holdings, Inc. by 55.4% in the second quarter, selling over 1.1 million shares. Despite this, other institutional investors increased their holdings, and the company reported strong Q2 EPS, beating analyst estimates. Analysts currently rate the stock as "Hold" with a consensus price target of $109.00.

**3. Laurel Wealth Advisors LLC Has $1.13 Million Position in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251130T115138 | Somewhat-Bullish | Relevance: 98%
- Laurel Wealth Advisors LLC significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9,021.3% to a total of 12,405 shares valued at $1.13 million. This increase comes as Zimmer Biomet reported strong Q3 earnings, beating EPS estimates, and provided positive FY2025 guidance. Institutional investors hold a significant portion of the company's stock, and analysts maintain a consensus "Hold" rating with a $109 price target.

**4. Hsbc Holdings PLC Has $34.05 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251202T094430 | Neutral | Relevance: 98%
- Hsbc Holdings PLC reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.3% in the second quarter, bringing its total holding to 373,505 shares valued at $34.05 million. Other hedge funds also adjusted their positions in ZBH. The article also provides analyst ratings, stock performance data, and details on recent insider trading activity for Zimmer Biomet.

**5. Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Vinva Investment Management Ltd**
- Source: MarketBeat | 20251130T133630 | Somewhat-Bullish | Relevance: 95%
- Vinva Investment Management Ltd increased its stake in Zimmer Biomet Holdings, Inc. by 42.9% in the second quarter, now owning 12,514 shares valued at $1.145 million. Institutional investors collectively own 88.89% of the stock, while corporate insiders hold 1.39%, with SVP Lori Winkler recently selling 1,500 shares. Analysts currently have an average "Hold" rating and a consensus price target of $109.00 for the company, which recently beat EPS estimates and provided positive FY2025 guidance.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 11.1x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.4B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 11.1 |
| Current P/E | 11.5 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.1% to 0.7% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.3pp (needs >4.0% for momentum thesis). MRS_5 (-2.8%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. MACD histogram positive (0.88), confirming momentum. RSI neutral at 49.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.66% (CS: 67) | Neutral |
| RSI_14 | 49.1 | Neutral |
| MACD Histogram | 0.88 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 0.950x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $94.14
- **Stop Loss:** $89.00 (5.5% risk)
- **Target:** $104.42 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 194
- **Position Value:** $18,263.16
- **Portfolio %:** 18.26%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*